Advertisement

Health


Telix Pharmaceuticals to raise $200m for final stage prostate cancer therapy trials

Telix Pharmaceuticals to raise $200m for final stage prostate cancer therapy trials

Melbourne-headquartered nuclear medicine company Telix Pharmaceutic...

Trajan Group is on a mission to democratise healthcare, one merger at a time

Trajan Group is on a mission to democratise healthcare, one merger at a time

Since listing on the ASX in mid-2021, analytical sciences company T...

UK private equity firm CapVest enters race for IVF giant Virtus Health with $649m bid

UK private equity firm CapVest enters race for IVF giant Virtus Health with $649m bid

Assisted reproductive services multinational Virtus Health (ASX: VR...

Bod to launch UK clinical trial into medicinal cannabis efficacy on long COVID

Bod to launch UK clinical trial into medicinal cannabis efficacy on long COVID

With an estimated 1.3 million people in the United Kingdom sufferin...

Ramsay Health Care to acquire UK mental health services provider for $1.4 billion

Ramsay Health Care to acquire UK mental health services provider for $1.4 billion

Australian healthcare giant Ramsay Health Care (ASX: RHC) has today...

Advertisement
Advertisement
Advertisement
Althea gets green light to sell Australian-made medicinal cannabis in Germany

Althea gets green light to sell Australian-made medicinal cannabis in Germany

Melbourne-based Althea Group (ASX: AGH) is on track to becoming t...

Class action "the only hope" for Smiles Inclusive partners on the sidelines

Class action "the only hope" for Smiles Inclusive partners on the sidelines

Smiles Inclusive (ASX: SIL) joint venture partners (JVPs) have ha...

CSL to build $800m flu vaccine facility in Melbourne

CSL to build $800m flu vaccine facility in Melbourne

Australia-headquartered CSL (ASX: CSL) is set to bring a cell-bas...

UQ COVID-19 vaccine "ahead of schedule", Phase 3 trials to commence soon

UQ COVID-19 vaccine "ahead of schedule", Phase 3 trials to commence soon

A COVID-19 vaccine being developed by the University of Queenslan...

Restrictions on ACT venues to ease tomorrow, patron cap will increase to 500

Restrictions on ACT venues to ease tomorrow, patron cap will increase to 500

The improving COVID-19 situation in Victoria and New South Wales ...

Mesoblast rebounds on COVID-19 treatment update, puts vaccine concerns to bed

Mesoblast rebounds on COVID-19 treatment update, puts vaccine concerns to bed

Melbourne-based med-tech company Mesoblast (ASX: MSB) has rebound...

Health fund backs medicinal cannabis with Little Green Pharma deal

Health fund backs medicinal cannabis with Little Green Pharma deal

Little Green Pharma (ASX: LGP) hopes a new strategic partnership ...

Smiles Inclusive enters voluntary administration

Smiles Inclusive enters voluntary administration

The local anaesthetic of turnaround promises has finally wor...

MedAdvisor to buy USA's largest patient-prescriber network Adheris for $49m

MedAdvisor to buy USA's largest patient-prescriber network Adheris for $49m

Medical software group MedAdvisor (ASX: MDR) is prepared to ...

Healthia to buy The Optical Company for $43 million

Healthia to buy The Optical Company for $43 million

Just one day after announcing yet another spending spree, allied ...

Atomo's COVID-19 nasal swab test gets green light from TGA

Atomo's COVID-19 nasal swab test gets green light from TGA

Sydney-based Atomo Diagnostics (ASX: AT1) has yet another feather...

Noxopharm starts trial in COVID-19 treatment race

Noxopharm starts trial in COVID-19 treatment race

Burgeoning medtech company Noxopharm (ASX: NOX) is making strides...

NAB tightens the screws on Smiles Inclusive

NAB tightens the screws on Smiles Inclusive

Smiles Inclusive (ASX: SIL) has been given a slight reprieve on a...

CSL seals deal to supply 51 million doses of UQ COVID-19 vaccine candidate

CSL seals deal to supply 51 million doses of UQ COVID-19 vaccine candidate

Biotechnology giant CSL (ASX: CSL) has finalised an agreement wit...

Mesoblast plunges as FDA orders additional trial of Ryoncil

Mesoblast plunges as FDA orders additional trial of Ryoncil

Shares in Mesoblast (ASX: MSB) were down 40 per cent this morning...

Advertisement

Partner Content

'Digitisation' and 'digitalisation' are two words t...
With the ongoing supply chain crisis expected to continue throughou...
From COVID-19 restrictions changing the way people shop, to supply ...
The last two years have delivered major disruption to the technolog...
If you are not reassessing how your organisation remunerates and re...
Three new qualifications at The University of Notre Dame Australia ...
Property developer Aspen Group has begun work to breathe new life i...
Golf Journeys, an Australian golf travel company, has big plan...
Advertisement